Auro Laboratories Ltd

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 June 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grading downgraded from Hold to Sell, reflecting a notable deterioration in its business fundamentals. Key financial parameters such as return on equity (ROE), return on capital employed (ROCE), and growth metrics have weakened, raising concerns about the company’s operational efficiency and financial health amid a challenging industry backdrop.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a positive financial performance for the quarter ended March 2026, with robust revenue growth and improved profitability. However, certain operational metrics indicate emerging challenges, prompting a reassessment of its investment grade from Buy to Hold by MarketsMOJO as of 2 March 2026.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market stance.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd has seen its investment rating downgraded from Buy to Hold as of 2 March 2026, reflecting a nuanced assessment across quality, valuation, financial trends, and technical indicators. Despite strong recent financial performance and impressive long-term returns, concerns over debt servicing ability and valuation metrics have tempered enthusiasm among analysts.

Auro Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 18 February 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Auro Laboratories Ltd has been upgraded from a Hold to a Buy rating by MarketsMOJO, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. The pharmaceutical company’s recent quarterly results, robust price momentum, and consistent long-term returns have collectively driven this positive reassessment, signalling renewed investor confidence in its growth prospects.

Auro Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross—a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-DMA. This development signals a potential bullish breakout and a long-term momentum shift, suggesting renewed investor confidence and a possible trend reversal in the stock’s trajectory.